Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 2
2001 6
2002 4
2003 5
2004 5
2005 4
2006 1
2007 4
2008 4
2009 8
2010 10
2011 12
2012 9
2013 16
2014 15
2015 3
2016 2
2017 3
2018 1
2019 2
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

98 results
Results by year
Filters applied: . Clear all
Page 1
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.
Mai EK, Bertsch U, Dürig J, Kunz C, Haenel M, Blau IW, Munder M, Jauch A, Schurich B, Hielscher T, Merz M, Huegle-Doerr B, Seckinger A, Hose D, Hillengass J, Raab MS, Neben K, Lindemann HW, Zeis M, Gerecke C, Schmidt-Wolf IG, Weisel K, Scheid C, Salwender H, Goldschmidt H. Mai EK, et al. Among authors: neben k. Leukemia. 2015 Aug;29(8):1721-9. doi: 10.1038/leu.2015.80. Epub 2015 Mar 19. Leukemia. 2015. PMID: 25787915 Clinical Trial.
Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders.
Ross FM, Avet-Loiseau H, Ameye G, Gutiérrez NC, Liebisch P, O'Connor S, Dalva K, Fabris S, Testi AM, Jarosova M, Hodkinson C, Collin A, Kerndrup G, Kuglik P, Ladon D, Bernasconi P, Maes B, Zemanova Z, Michalova K, Michau L, Neben K, Hermansen NE, Rack K, Rocci A, Protheroe R, Chiecchio L, Poirel HA, Sonneveld P, Nyegaard M, Johnsen HE; European Myeloma Network. Ross FM, et al. Among authors: neben k. Haematologica. 2012 Aug;97(8):1272-7. doi: 10.3324/haematol.2011.056176. Epub 2012 Feb 27. Haematologica. 2012. PMID: 22371180 Free PMC article.
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.
Baertsch MA, Mai EK, Hielscher T, Bertsch U, Salwender HJ, Munder M, Fuhrmann S, Dührsen U, Brossart P, Neben K, Schlenzka J, Kunz C, Raab MS, Hillengaß J, Jauch A, Seckinger A, Hose D, Luntz S, Sonneveld P, Lokhorst H, Martin H, Goerner M, Hoffmann M, Lindemann HW, Bernhard H, Blau IW, Scheid C, Besemer B, Weisel KC, Hänel M, Dürig J, Goldschmidt H; German-Speaking Myeloma Multicenter Group (GMMG). Baertsch MA, et al. Among authors: neben k. Blood Cancer J. 2021 Jan 7;11(1):1. doi: 10.1038/s41408-020-00390-3. Blood Cancer J. 2021. PMID: 33414374 Free PMC article.
Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma.
Merz M, Hielscher T, Mai EK, Seckinger A, Hose D, Jauch A, Sauer S, Luntz S, Bertsch U, Raab MS, Neben K, Salwender H, Blau IW, Lindemann HW, Dürig J, Scheid C, Haenel M, Weisel K, Weber T, Delorme S, Goldschmidt H, Hillengass J. Merz M, et al. Among authors: neben k. Blood Cancer J. 2019 Aug 27;9(9):71. doi: 10.1038/s41408-019-0235-3. Blood Cancer J. 2019. PMID: 31455768 Free PMC article. No abstract available.
Centrosome aberrations in hematological malignancies.
Krämer A, Neben K, Ho AD. Krämer A, et al. Among authors: neben k. Cell Biol Int. 2005 May;29(5):375-83. doi: 10.1016/j.cellbi.2005.03.004. Cell Biol Int. 2005. PMID: 15996491 Review.
Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma.
Mai EK, Hielscher T, Bertsch U, Schlenzka J, Salwender HJ, Munder M, Gerecke C, Dührsen U, Brossart P, Neben K, Hillengass J, Raab MS, Merz M, Baertsch MA, Jauch A, Hose D, Martin H, Lindemann HW, Blau IW, Scheid C, Weisel KC, Goldschmidt H; German-speaking Myeloma Multicenter Group (GMMG). Mai EK, et al. Among authors: neben k. Leukemia. 2019 Jan;33(1):258-261. doi: 10.1038/s41375-018-0195-9. Epub 2018 Jun 29. Leukemia. 2019. PMID: 29959413 Clinical Trial. No abstract available.
Angiogenesis in hematologic malignancies.
Moehler TM, Neben K, Ho AD, Goldschmidt H. Moehler TM, et al. Among authors: neben k. Ann Hematol. 2001 Dec;80(12):695-705. doi: 10.1007/s00277-001-0398-3. Epub 2001 Nov 14. Ann Hematol. 2001. PMID: 11797109 Review.
Targeting the BRAF V600E mutation in multiple myeloma.
Andrulis M, Lehners N, Capper D, Penzel R, Heining C, Huellein J, Zenz T, von Deimling A, Schirmacher P, Ho AD, Goldschmidt H, Neben K, Raab MS. Andrulis M, et al. Among authors: neben k. Cancer Discov. 2013 Aug;3(8):862-9. doi: 10.1158/2159-8290.CD-13-0014. Epub 2013 Apr 23. Cancer Discov. 2013. PMID: 23612012 Free article.
98 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page